Conducting clinical trials in rare diseases and advancing research pipelines requires a collaborative, multi-stakeholder approach. This process requires cooperation from industry, academic researchers, advocacy groups, and patients as well as their caregivers and families. In this white paper, we look at the barriers drug developers face when positioning a new trial in the rare disease space and how to minimize these barriers by applying a multi-stakeholder collaborative approach to drug development.
Clinical Trials in Children with Impaired Mental Capacity
Download this resource to learn how to conduct studies with patients who lack legal competence and the 4 ethical pillars of medical research.
IIT Program Management Case Study
6+ year relationship with a large biopharma company that needed to change the operating model for their investigator-initiated trials (IIT), in part…
PRA Cool Under Deadline Pressure
PRA was selected to perform a Phase II colorectal cancer trial due to our knowledge from previous colorectal studies as well as our evidence-based…